Arsanis Wins Grant

Arsanis Biosciences, an early stage biotechnology company developing anti-infective human monoclonal antibodies, has been awarded a grant for the development of monoclonal antibody therapeutics against nosocomial infections from the Austrian Research Promotion Agency (Forschungs-Forderungs-Gesellschaft or "FFG"), the public funding agency for translational research in Austria. The support from FFG for the first year is 1.19 million euros ($1.63 million); additional funding (up to 70% of the total budget of 12.5 million euros ($17.2 million) for the program) is expected in the following three years.

North AmericaUSBriefs